Corvus To Initially Retain 49.7% Stake In Angel Pharma - Quick Facts

Corvus Pharmaceuticals Inc. (CRVS) said it will initially retain a 49.7% equity stake in Angel Pharmaceuticals and will be entitled to designate three individuals on Angel's five-person Board of Directors, as part of a collaboration between them.

Angel Pharmaceuticals licensed the rights to develop and commercialize Corvus' three clinical-stage candidates - ciforadenant, CPI-006 and CPI-818 - in China and obtained global rights to Corvus' BTK inhibitor preclinical programs.

Angel has launched with $41 million financing backed by local investor group which includes three prominent biopharmaceutical companies.

".. We have already begun working with the Angel leadership to initiate clinical trials in China with ciforadenant, CPI-006 and CPI-818 in cancer, autoimmune diseases and infectious diseases within the next 12 to 18 months,"said Richard Miller, president and chief executive officer of Corvus.

Angel will be responsible for the clinical development and commercialization, including all related expenses, of the licensed pipeline programs in China, and for the pre-clinical BTK program globally. It plans to initiate clinical trials in China for ciforadenant, CPI-006 and CPI-818 in the next 12 to 18 months.

In the United States, Corvus is planning to meet with the U.S. Food & Drug Administration in December 2020 to discuss the study design and plans for a pivotal ciforadenant study in advanced refractory renal cell cancer (RCC) using the Adenosine Gene Signature as a biomarker.

Angel plans to expand its team with leading scientific talent in China. In addition, Miller, a co-founder of Angel, will serve as Chairman of the Board and interim chief executive officer, working closely with the founding leadership team.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration is looking to set a new framework to further improve and maintain the supply of infant formula to ensure that American consumers have access to safe and nutritious infant formula. Infant formula is an essential food product that is the sole source of nutrition for many babies in the U.S. Amazon has unveiled millions of deals worldwide that will be available during its upcoming Prime Day extravaganza. The 48-hour shopping event for Prime members kicks off July 12 at 3 a.m. EDT, offering deals of up to 79% off across various categories. These include electronics, devices, toys, beauty, fashion, and home, from top national brands and small businesses. Primal Pet Foods is recalling a single lot of Raw Frozen Primal Patties for Dogs Beef Formula due to potential contamination with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves lot #W10068709 of 6-pound Raw Frozen Primal Patties with best by date of 05/22/23. The Raw Frozen Primal Patties are sold in flexible packaging in the freezer at select pet stores.
Follow RTT